Show simple item record

dc.contributor.authorEconomopoulou, P.en
dc.contributor.authorMountzios, G.en
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorPentheroudakis, Georgeen
dc.creatorEconomopoulou, P.en
dc.creatorMountzios, G.en
dc.creatorPavlidis, Nicholasen
dc.creatorPentheroudakis, Georgeen
dc.date.accessioned2018-06-22T09:52:57Z
dc.date.available2018-06-22T09:52:57Z
dc.date.issued2015
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41581
dc.description.abstractCancer of Unknown Primary (CUP) comprises a heterogeneous disease group with diagnosis of metastatic malignancy in the absence of an identifiable primary site after diagnostic work up. CUP may either resemble a specific primary tumor site sharing common clinicopathological characteristics and prognosis, or present as a distinct disease entity with undifferentiated pathological features, usually bearing dismal prognosis. Diagnosis and management have traditionally been based on clinicopathological characteristics and therapeutic strategies have been mainly empirical. In the last decade, the advent of massive gene sequencing and the advances in genomic technologies have shed light on the genomic landscape of CUP. Several gene panel tests are currently commercially available and are used in an effort to correlate the genomic characteristics of a specific CUP tumor to those of a known primary tumor, guiding thus therapeutic management. Nevertheless, these efforts are hampered by the rarity of CUP and the inability to validate the results of such tests due to the paucity of randomized clinical trials. In the current work, we provide an overview of CUP with emphasis on the impact of the genome sequencing technologies on diagnosis and management of these tumors. We also discuss potential implications of genomics for the future treatment of CUP and address the challenges of the implementation of these therapeutic strategies in routine clinical practice. © 2015 Elsevier Ltd.en
dc.language.isoengen
dc.sourceCancer treatment reviewsen
dc.subjectReviewen
dc.subjectCancer chemotherapyen
dc.subjectCisplatinen
dc.subjectEtoposideen
dc.subjectHumanen
dc.subjectNeoplasmsen
dc.subjectHumansen
dc.subjectAdvanced canceren
dc.subjectCancer survivalen
dc.subjectCarboplatinen
dc.subjectPaclitaxelen
dc.subjectPrognosisen
dc.subjectGemcitabineen
dc.subjectCancer diagnosisen
dc.subjectCancer prognosisen
dc.subjectImmunohistochemistryen
dc.subjectTumor differentiationen
dc.subjectProceduresen
dc.subjectCancer of unknown primary siteen
dc.subjectUnknown primaryen
dc.subjectTumor markeren
dc.subjectCytokeratinen
dc.subjectGenomicsen
dc.subjectPersonalized medicineen
dc.subjectMicrornaen
dc.subjectGene expression profilingen
dc.subjectBelinostaten
dc.subjectCancer of unknown primaryen
dc.subjectCetuximaben
dc.subjectClinical evaluationen
dc.subjectDna microarrayen
dc.subjectGenomicen
dc.subjectMessenger rnaen
dc.subjectMolecular profiling assaysen
dc.subjectNext generation sequencingen
dc.subjectReverse transcription polymerase chain reactionen
dc.subjectVandetaniben
dc.titleCancer of Unknown Primary origin in the genomic era: Elucidating the dark box of canceren
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.ctrv.2015.05.010
dc.description.volume41
dc.description.issue7
dc.description.startingpage598
dc.description.endingpage604
dc.author.facultyΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.contributor.orcidPentheroudakis, George [0000-0002-6632-2462]
dc.contributor.orcidEconomopoulou, P. [0000-0001-8871-3264]
dc.gnosis.orcid0000-0002-2195-9961
dc.gnosis.orcid0000-0002-6632-2462
dc.gnosis.orcid0000-0001-8871-3264


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record